Article
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Jul 2020
Stenzinger Albrecht, Endris Volker, Budczies Jan, Merkelbach-Bruse Sabine, Kazdal Daniel, Dietmaier Wolfgang, Pfarr Nicole, Siebolts Udo, Hummel Michael, Herold Sylvia, Andreas Johanna, Zoche Martin, Tögel Lars, Rempel Eugen, Maas Jörg, Merino Diana, Stewart Mark, Zaoui Karim, Schlesner Matthias, Glimm Hanno, Fröhling Stefan, Allen Jeff, Horst David, Baretton Gustavo, Wickenhauser Claudia, Tiemann Markus, Evert Matthias, Moch Holger, Kirchner Thomas, Büttner Reinhard, Schirmacher Peter, Jung Andreas, Haller Florian, Weichert Wilko, Dietel Manfred
Abstract excerpt
INTRODUCTION: Tumor mutational burden (TMB) is a quantitative assessment of the number of somatic mutations within a tumor genome. Immunotherapy benefit has been associated with TMB assessed by whole-exome sequencing (wesTMB) and gene panel sequencing (psTMB). The initiatives of Quality in Pathology (QuIP) and Friends of Cancer Research have jointly addressed the need for harmonization among TMB testing options...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
